晨光生物(300138.SZ)半年度淨利潤預增19.05%至28.26%
格隆匯7月13日丨晨光生物(300138.SZ)公佈,預計2021年半年度歸屬於上市公司股東的淨利潤1.81億元-1.95億元,同比增長19.05%至28.26%;營業收入20.5億元-21.8億元,同比增長12.27%至19.39%。
公司繼續堅持“以客户為中心”,為客户創造價值,不斷提升行業影響力。報吿期內主產品持續發力,辣椒紅色素銷量和收入同比增長;辣椒精售價上揚,銷售收入同比增長;葉黃素價格波動較小,受銷售節奏影響二季度銷售量同比下降;潛力品種(如:花椒提取物、甜菊糖、薑黃素、番茄紅素、水飛薊提取物等)快速發展,促進了公司業績的增長。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.